Study finds colesevelam effective in reducing LDL cholesterol

October 22, 2001

ROCHESTER, MINN. -- Colesevelam hydrochloride appears to be an effective lipid-lowering agent that significantly reduces low-density lipoprotein (LDL) cholesterol levels, according to a study published in the October issue of Mayo Clinic Proceedings.

The researchers involved in the double-blind, placebo-controlled trial concluded that colesevelam was efficacious, decreasing mean LDL levels by up to 18 percent, and was well-tolerated without serious adverse events. Elevated LDL cholesterol is a major risk factor contributing to the development and progression of atherosclerotic disease and coronary heart disease. Atherosclerotic coronary heart disease is a major cause of death and disability, affecting approximately 14 million adults in the United States.

"Past clinical studies have shown that cholesterol-lowering therapy is effective in reducing the risk of coronary heart disease as well as decreasing coronary events in patients with established coronary heart disease," says Michael H. Davidson, M.D., senior author of the study. "Colesevelam appears to be a useful therapeutic alternative for patients with mild to moderate primary hypercholesterolemia."

Hypercholesterolemia occurs when abnormally high concentrations of cholesterol are present in the bloodstream. It can lead to heart disease, hardening of the arteries, heart attack and strokes.

Colesevelam was administered for treatment of mild to moderate hypercholesterolemia in a randomized, double-blind, placebo-controlled multicenter trial in 1998. The 18-center study had 494 patients during the 24-week treatment period. Colesevelam lowered mean LDL levels from nine percent to 18 percent. Mean total cholesterol levels decreased four percent to 10 percent.

The researchers note that the degree of lipid lowering with colesevelam was independent of sex or age. Furthermore, colesevelam treatment was not accompanied by serious adverse events relative to placebo.
Joining Dr. Davidson of the Chicago Center for Clinical Research in authoring this study were: William Insull Jr., M.D., of the Baylor College of Medicine, Lipid Research Clinic; Phillip Toth, M.D., Midwest Institute for Clinical Research, Inc., Indianapolis, Ind.; William Mullican, M.D., MediSphere Medical Research Center, LLC, Evansville, Ind.; Donald Hunninghake, M.D., University of Minnesota, Heart Disease Prevention Clinic; Steven Burke, M.D., and Joanne M. Donovan, M.D., Ph.D., both of GelTex Pharmaceuticals, Inc., Waltham, Mass.

The study was funded by GelTex Pharmaceuticals, Inc., Waltham, Mass., the developer of colesevelam. Drs. Hunninghake and Davidson have served as consultants to GelTex Pharmaceuticals, Inc.

Mayo Clinic Proceedings is a peer-reviewed and indexed general internal medicine journal, published for 75 years by Mayo Foundation, with a circulation of 130,000 nationally and internationally.

To obtain news releases from Mayo Clinic, go to ( is available as a resource for your health stories (note name change from Mayo Clinic Health Oasis/

Oct. 22, 2001
John Murphy
507-284-5005 (days)
507-284-2511 (evenings)

Mayo Clinic

Related Heart Disease Articles from Brightsurf:

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

New 'atlas' of human heart cells first step toward precision treatments for heart disease
Scientists have for the first time documented all of the different cell types and genes expressed in the healthy human heart, in research published in the journal Nature.

With a heavy heart: How men and women develop heart disease differently
A new study by researchers from McGill University has uncovered that minerals causing aortic heart valve blockage in men and women are different, a discovery that could change how heart disease is diagnosed and treated.

Heart-healthy diets are naturally low in dietary cholesterol and can help to reduce the risk of heart disease and stroke
Eating a heart-healthy dietary pattern rich in vegetables, fruits, whole grains, low-fat dairy products, poultry, fish, legumes, vegetable oils and nuts, which is also limits salt, red and processed meats, refined-carbohydrates and added sugars, is relatively low in dietary cholesterol and supports healthy levels of artery-clogging LDL cholesterol.

Pacemakers can improve heart function in patients with chemotherapy-induced heart disease
Research has shown that treating chemotherapy-induced cardiomyopathy with commercially available cardiac resynchronization therapy (CRT) delivered through a surgically implanted defibrillator or pacemaker can significantly improve patient outcomes.

Arsenic in drinking water may change heart structure raising risk of heart disease
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, according to a new study by researchers at Columbia University Mailman School of Public Health.

New health calculator can help predict heart disease risk, estimate heart age
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health status and lifestyle behaviors.

Wide variation in rate of death between VA hospitals for patients with heart disease, heart failure
Death rates for veterans with ischemic heart disease and chronic heart failure varied widely across the Veterans Affairs (VA) health care system from 2010 to 2014, which could suggest differences in the quality of cardiovascular health care provided by VA medical centers.

Heart failure: The Alzheimer's disease of the heart?
Similar to how protein clumps build up in the brain in people with some neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, protein clumps appear to accumulate in the diseased hearts of mice and people with heart failure, according to a team led by Johns Hopkins University researchers.

Read More: Heart Disease News and Heart Disease Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to